Patterns of referral for perioperative chemotherapy among patients with muscle-invasive bladder cancer: A population-based study

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 8, 2014, Pages 1200-1208

  Booth, Christopher M ^a,b   Robert Siemens, David ^b   Peng, Yingwei ^a,b   Mackillop, William J ^a,b  

^a QUEEN S UNIVERSITY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

Bladder cancer; Chemotherapy; Health services research; Knowledge translation; Quality of care; Surgery

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANADA; CANCER ADJUVANT THERAPY; CLINICAL PRACTICE; COHORT ANALYSIS; COMORBIDITY; CYSTECTOMY; ELECTRONIC MEDICAL RECORD; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUSCLE INVASIVE BLADDER CANCER; ONCOLOGY; PATIENT REFERRAL; PERIOPERATIVE PERIOD; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOCIAL STATUS; UROLOGY; VERY ELDERLY; ADJUVANT CHEMOTHERAPY; HEALTH CARE QUALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TUMOR INVASION; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COMBINED MODALITY THERAPY; COMORBIDITY; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; ONTARIO; PERIOPERATIVE CARE; QUALITY OF HEALTH CARE; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 84925853751     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2014.05.012     Document Type: Article

References (30)

1. Winquist E, Waldron T, Segal R, Chin J, Likka H. Use of neoadjuvant chemotherapy in transitional cell carcinoma of the bladder Practice Guideline Report #3-2-2. Cancer Care Ontario Program in Evidence-Based Care, editor.; 2005 [Ref Type: Report, accessed on 9.05.2013]. https://www.cancercare.on.ca/toolbox/qualityguidelines/diseasesite/genito-ebs/.
2. Sternberg C.N., Donat S.M., Bellmunt J., Millikan R.E., Stadler W., De Mulder P., et al. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology 2007, 69(Suppl. 1):62-79.
3. Bellmunt J., Albiol S., Kataja V. Invasive bladder cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009, 20(Suppl. 4):79-80.
4. Segal R., Winquist E., Lukka H., Chin J.L., Brundage M., Markman B.R. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma-a practice guideline. Can J Urol 2002, 9:1625-1633.
5. Porter M.P., Kerrigan M.C., Donato B.M.K., et al. Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. Urol Oncol 2011, 29:252-258.
6. David K.A., Milowsky M.I., Ritchey J., Carroll P.R., Nanus D.M. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol 2007, 178:451-454.
7. Snyder C., Harlan L., Knopf K., Potosky A., Kaplan R. Patterns of care for the treatment of bladder cancer. J Urol 2003, 169:1697-1701.
8. Schrag D., Mitra N., Xu F., Rabbani F., Bach P.B., Herr H., et al. Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population. Urology 2005, 65:1118-1125.
9. Booth CM, Siemens DR, Li G, Peng Y, Tannock IF, Kong W, et al. Peri-operative chemotherapy for muscle-invasive bladder cancer: a population-based outcomes study. Cancer [in press]. http://www.ncbi.nlm.nih.gov/pubmed/24733278.
10. Bajorin D.F., Herr H.W. Kuhn[U+05F3]s paradigms: are those closest to treating bladder cancer the last to appreciate the paradigm shift?. J Clin Oncol 2011, 29:2135-2137.
11. Raghavan D. Invasive bladder cancer: ignoring the data. Oncologist 2013, 18:895-896.
12. Patafio FM, Mackillop WJ, Fedlman-Stewart D, Siemens DR, Booth CM. Why is perioperative chemotherapy for bladder cancer underutilized? Urol Oncol. [in press]. http://www.ncbi.nlm.nih.gov/pubmed/24508282.
13. Rehman S., Crane A., Din R., Raza S.J., Shi Y., Wilding G., et al. Understanding avoidance, refusal, and abandonment of chemotherapy before and after cystectomy for bladder cancer. Urology 2013, 82:1370-1375.
14. Miles B.J., Fairey A.S., Eliasziw M., Estey E.P., Venner P., Finch D., et al. Referral and treatment rates of neoadjuvant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guideline. Can Urol Assoc J 2010, 4:263-267.
15. Clarke E.A., Marrett L.D., Krieger N. Cancer registration in Ontario: a computer approach. Cancer registration principles and methods 1991, 246-257. IARC, Lyon, France. O.M. Jenson, D.M. Parkin, R. MacLennan (Eds.).
16. Booth C.M., Li G., Zhang-Salomons J, Mackillop W.J. The impact of socioeconomic status on stage of cancer at diagnosis and survival: a population-based study in Ontario, Canada. Cancer 2010, http://www.ncbi.nlm.nih.gov/pubmed/20681012.
17. Deyo R.A., Cherkin D.C., Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992, 45:613-619.
18. Kankesan J., Shepherd F.A., Peng Y., Darling G., Li G., Kong W., et al. Factors associated with referral to medical oncology and subsequent use of adjuvant chemotherapy for non-small-cell lung cancer: a population-based study. Curr Oncol 2013, 20:30-37.
19. Mackillop W.J. Health services research in radiation oncology: toward achieving the achievable. Clinical radiation oncology 2007, 215-237. Churchill Livingstone, Philadelphia, PA. L.L. Gunderson, J.E. Tepper (Eds.).
20. Thompson R.H., Boorjian S.A., Kim S.P., Cheville J.C., Thapa P., Tarrel R., et al. Eligibility for neoadjuvant/adjuvant cisplatin-based chemotherapy among radical cystectomy patients. BJU Int 2013, [Epub ahead of print]. http://www.ncbi.nlm.nih.gov/pubmed/24006893.
21. Canter D., Viterbo R., Kutikov A., Wong Y.N., Plimack E., Zhu F., et al. Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomy. Urology 2011, 77:160-165.
22. Booth C.M., Shepherd F.A., Peng Y., Darling G.E., Li G., Kong W., et al. Adoption of adjuvant chemotherapy for non-small-cell lung cancer: a population-based outcomes study. J Clin Oncol 2010, 28:3472-3478.
23. Bhargava A., Du X.L. Racial and socioeconomic disparities in adjuvant chemotherapy for older women with lymph node-positive, operable breast cancer. Cancer 2009, 115:2999-3008.
24. Schrag D., Cramer L.D., Bach P.B., Begg C.B. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 2001, 93:850-857.
25. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 1999, 354:533-540. International collaboration of trialists.
26. Grossman H.B., Natale R.B., Tangen C.M., Speights V.O., Vogelzang N.J., Trump D.L., et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003, 349:859-866.
27. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur Urol 2005, 48:202-205. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration.
28. Segal R, Winquist E, Lukka H, et al. Use of Adjuvant chemotherapy following cystectomy in patients with deep muscle-invasive transitional cell carcinoma of the Bladder Practice Guideline Report #3-2-1. Cancer Care Ontario Program in Evidence-Based Care, editor.; 2003 [Ref Type: Report, accessed 9.05.2013]. https://www.cancercare.on.ca/toolbox/qualityguidelines/diseasesite/genito-ebs/.
29. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data. Eur Urol 2005, 48:189-199. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration.
30. Booth C.M., Mackillop W.J. Translating new medical therapies into societal benefit: the role of population-based outcome studies. J Am Med Assoc 2008, 300:2177-2179.